PSYCHEDELICS IN PSYCHIATRY — BIG HYPE, SMALL TRIALS, REAL RISKS

PSYCHEDELICS IN PSYCHIATRY — BIG HYPE, SMALL TRIALS, REAL RISKS

Psychedelic-assisted therapies, including psilocybin- and MDMA-based interventions, demonstrate promising but preliminary efficacy for certain psychiatric conditions, particularly treatment-resistant depression and post-traumatic stress disorder. However, the current evidence base is derived predominantly from small, highly controlled clinical trials with carefully selected participants, intensive therapeutic support, and methodological limitations (including challenges with blinding and expectancy effects).

Until such evidence is established, first-line treatment should remain evidence-based pharmacotherapy and psychotherapy with well-characterized efficacy and safety profiles.

BIG PHARMA BUYS AND BURIES INNOVATIVE COMPANIES USING ANTICOMPETITIVE MERGERS

BIG PHARMA BUYS AND BURIES INNOVATIVE COMPANIES USING ANTICOMPETITIVE MERGERS

U.S. antitrust policy should be strengthened to address anticompetitive mergers in the pharmaceutical sector, particularly “killer acquisitions” that eliminate emerging competition. This includes lowering reporting thresholds in highly concentrated health care markets, requiring the inclusion of intangible assets such as patents in merger evaluations, and applying heightened scrutiny to transactions involving overlapping products. Regulators, including the Federal Trade Commission and the Department of Justice, should also require enforceable commitments to continued product development and post-merger transparency. These reforms would help preserve competition, promote innovation, and protect patients from high prices and reduced access to essential therapies.

COVID-19 and the EPSTEIN FILES

COVID-19 and the EPSTEIN FILES

The Coronavirus and mRNA patents and medical papers evolved from 1989 onward. In 1999 Bill Gates had to re-brand himself and started Global Alliance for Vaccines and Immunization to market vaccines.

In Feb 2011, he “specifically requested” Epstein’s help. Epstein created a pre-COVID operational structure — financialized, globally coordinated, and partially integrated with Pentagon biodefense systems — that he built, staffed, and rehearsed. Epstein put himself at the junction of these systems, linking philanthropic capital, Wall Street finance, global health governance, and Pentagon biosecurity research.

SHARED CLINICAL DECISION-MAKING: When Medical Uncertainty Shifts the Burden of Complex Health Decisions onto Patients

SHARED CLINICAL DECISION-MAKING: When Medical Uncertainty Shifts the Burden of Complex Health Decisions onto Patients

In principle, shared clinical decision-making aims to make care more individualized and collaborative. In practice, however, it can place complex judgments about uncertain evidence into the hands of patients who may have limited time, information, or technical expertise to fully evaluate the choices.

CORPORATE TAKEOVERS ARE CHANGING U.S. HEALTHCARE

CORPORATE TAKEOVERS ARE CHANGING U.S. HEALTHCARE

Big investors are buying hospitals, nursing homes, and doctor’s practices. This can bring money and technology—but often puts profits over patients.

Costs up, quality down: Private equity nursing homes have worse staffing and outcomes. Hospital mergers drive prices up.
Doctors under pressure: Loopholes let corporations control practices behind the scenes.

Solutions: Transparency on ownership, quality standards, smarter Medicare/Medicaid rules, and stronger oversight.